We are upgrading the repository! A content freeze is in effect until December 6th, 2024 - no new submissions will be accepted; however, all content already published will remain publicly available. Please reach out to repository@u.library.arizona.edu with your questions, or if you are a UA affiliate who needs to make content available soon. Note that any new user accounts created after September 22, 2024 will need to be recreated by the user in November after our migration is completed.

Show simple item record

dc.contributor.advisorVanderah, Todd W.
dc.contributor.authorZhang, Hong
dc.creatorZhang, Hong
dc.date.accessioned2020-05-22T21:56:51Z
dc.date.available2020-05-22T21:56:51Z
dc.date.issued2020
dc.identifier.urihttp://hdl.handle.net/10150/641370
dc.description.abstractChronic pain is a severe problem affecting over 20% of adults worldwide. Opioids, as the current most effective analgesics, are commonly prescribed to manage this devastating symptom. However, the use of opioids is frequently associated with serious side effects, such as respiratory depression and bone degradation. In addition, as opioids possess a profound addiction potential, the wide prescription of opioids has led to a severe opioid epidemic in North American, particularly in the United States. Recently, the endogenous cannabinoid system has emerged as a promising therapeutic target for the treatment of chronic pain and opioid addiction. However, there are still many questions in need of answers before we can translate current research into clinical application. In the present study, we sought to answer two major questions: (1) How can we develop a novel cannabinoid that produces a strong analgesic effect but has limited central side effects? (2) How the endocannabinoid 2-AG and cannabinoid receptor 2 (CB2R) are involved in the chronic opioid-induced reward? Our studies have found that targeting the peripheral CB1Rs can effectively attenuate pain behaviors in a syngeneic murine model of cancer-induced bone pain and results in limited central side effects, as well as other cannabinoid-associated side effects. Furthermore, the elevation of 2-AG tone and activation of CB2Rs remarkedly inhibits chronic morphine-induced reward behavior. Yet, chronic morphine exposure reduces the expression of CB2Rs but does not significantly change the production of 2-AG in the VTA. These data suggest that (1) targeting peripheral CB1Rs can be a valuable therapeutic strategy for treating cancer-induced bone pain, and (2) promoting 2-AG and CB2R signaling may provide therapeutic opportunity for opioid addiction.
dc.language.isoen
dc.publisherThe University of Arizona.
dc.rightsCopyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction, presentation (such as public display or performance) of protected items is prohibited except with permission of the author.
dc.subjectcancer-induced bone pain
dc.subjectEndogenous cannabinoid system
dc.subjectopioid-induced reward
dc.titleThe Roles of the Endogenous Cannabinoid System in Cancer-Induced Bone Pain and Opioid-Induced Reward
dc.typetext
dc.typeElectronic Dissertation
thesis.degree.grantorUniversity of Arizona
thesis.degree.leveldoctoral
dc.contributor.committeememberFrench, Edward D.
dc.contributor.committeememberIbrahim, Mohab M.
dc.contributor.committeememberLargent-Milnes, Tally M.
dc.contributor.committeememberStreicher, John M.
thesis.degree.disciplineGraduate College
thesis.degree.disciplineMedical Pharmacology
thesis.degree.namePh.D.
refterms.dateFOA2020-05-22T21:56:52Z


Files in this item

Thumbnail
Name:
azu_etd_17791_sip1_m.pdf
Size:
4.617Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record